Mineralys Therapeutics, Inc. (MLYS) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 143 transactions totaling $174.5M, demonstrating a bullish sentiment with $18.9M in net insider flow. The most recent transaction on Feb 19, 2026 involved a transaction of 53,300 shares valued at $0.
No significant insider buying has been recorded for MLYS in the recent period.
No significant insider selling has been recorded for MLYS in the recent period.
Based on recent SEC filings, insider sentiment for MLYS is bullish with an Insider Alignment Score of 55/100 and a net flow of $18.9M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Mineralys Therapeutics, Inc. (MLYS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading MLYS stock, having executed 143 transactions in the past 90 days. The most active insider is Capital Management, L.p. Ra (Executive), who has made 4 transactions totaling $52.6M.
Get notified when executives and directors at MLYS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Scott Levy Adam | CFO and Secretary | Award | 53,300 | $N/A | $0 | C-Suite |
| Feb 19, 2026 | Scott Levy Adam | CFO and Secretary | Award | 39,900 | $N/A | $0 | C-Suite |
| Feb 19, 2026 | Malcom Rodman David | Chief Medical Officer | Award | 51,300 | $N/A | $0 | |
| Feb 19, 2026 | Malcom Rodman David | Chief Medical Officer | Award | 38,400 | $N/A | $0 | |
| Feb 19, 2026 | Dirocco Derek | Executive | Award | 8,300 | $N/A | $0 | |
| Feb 19, 2026 | Dirocco Derek | Executive | Award | 6,200 | $N/A | $0 | |
| Feb 19, 2026 | Akkaraju Srinivas | Executive | Award | 8,300 | $N/A | $0 | |
| Feb 19, 2026 | Akkaraju Srinivas | Executive | Award | 6,200 | $N/A | $0 | |
| Feb 19, 2026 | Karydas Daphne | Executive | Award | 8,300 | $N/A | $0 | |
| Feb 19, 2026 | Karydas Daphne | Executive | Award | 6,200 | $N/A | $0 | |
| Feb 19, 2026 | M. Gold Alexander | Executive | Award | 8,300 | $N/A | $0 | |
| Feb 19, 2026 | M. Gold Alexander | Executive | Award | 6,200 | $N/A | $0 | |
| Feb 19, 2026 | Sblendorio Glenn | Executive | Award | 8,300 | $N/A | $0 | |
| Feb 19, 2026 | Sblendorio Glenn | Executive | Award | 6,200 | $N/A | $0 | |
| Feb 19, 2026 | Congleton Jon | Executive | Award | 187,900 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 13 | $96.7M | 46.7% |
Sale(S) | 58 | $77.8M | 37.6% |
Award(A) | 20 | $30.1M | 14.5% |
Exercise(M) | 46 | $2.4M | 1.2% |
Conversion(C) | 6 | $0 | 0.0% |
Insider activity at Mineralys Therapeutics, Inc. shows mixed signals across all time. While $96.7M in purchases indicates some executive confidence,$77.8M in sales balances the picture, resulting in a modest net flow of $18.9M.14 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Capital Management, L.p. Ra, has transacted $52.6M during this period.